유럽의 유전자 검사 서비스 시장 예측(-2030년) - 지역별 분석 : 서비스 유형별, 질환별, 서비스 프로바이더별

The Europe genetic testing services market was valued at US$ 931.11 million in 2022 and is expected to reach US$ 2,778.42 million by 2030; it is estimated to register a CAGR of 14.6% from 2022 to 2030.

Increasing Awareness and Acceptance of Personalized Medicines Drive Europe Genetic Testing Services Market

Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The successful completion of the Human Genome Project (HGP) in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach, which is called personalized medicine. With an expanding repository of personalized data at the molecular level, molecular diagnostics companies are exceptionally positioned to unlock value. Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders. Genomics is one of the fastest-growing divisions of medical science. It is driving a paradigm shift in the research methodology of a disease, as well as diagnosing and treating illness. Genetic testing has been extensively used in pharmacogenomics, also known as drug-gene testing. It helps in accelerating drug discovery and its development. France also developed a national plan for personalized medicine known as "Genomic Medicine France 2025." The program was presented to Prime Minister Manuel Valls by Yves Levy, President of the National Alliance for Life and Health Sciences-Aviesan and CEO of Inserm, in June 2016. It appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms. The plan was supported by the government and launched with a public financing of US$ 760.8 million (€670 million) in 2020 for genomics and personalized medicine programs. It is expected to place France as a leader among countries involved in genomic medicine within the next ten years. In January 2023, The Human Genome Project is ensuring an era of personalized healthcare. Now, new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption. Published by Cambridge University Press, the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale. These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care. Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care. Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease, the impact of treatment, and the development of therapies for specific individual characteristics. It also helps healthcare personnel make informed decisions about disease diagnosis, treatment, and prevention by utilizing genetic testing results, leading to improved patient outcomes.

Europe Genetic Testing Services Market Overview

European genetic testing services market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Genetic testing has been growing at an exceptional rate; a large panel of tests are now offered to screen a number of genetic diseases. Treatments are available for a number of rare genetic diseases, and the process is gaining importance in scenarios such as carrier testing, newborn screening, and predictive and pre-symptomatic testing, among others. Moreover, European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing. The ultimate goal is to ensure that all aspects of genetic testing are of high quality, thereby providing accurate and reliable results for the benefit of the patients.

Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Million)

Europe Genetic Testing Services Market Segmentation

The Europe genetic testing services market is categorized into service type, disease, service provider, and country.

Based on service type, the Europe genetic testing services market is segmented predictive testing, carrier testing, prenatal testing, newborn screening, and others. The predictive testing segment held the largest market share in 2022.

In terms of disease, the Europe genetic testing services market is categorized into cancer, metabolic diseases, cardiovascular diseases, and other diseases. The cancer segment held the largest market share in 2022.

By service provider, the Europe genetic testing services market is segmented into hospital-based laboratories, diagnostic laboratories, and others. The hospital-based laboratories segment held the largest market share in 2022.

By country, the Europe genetic testing services market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe genetic testing services market share in 2022.

Eurofins Scientific SE, Exact Sciences Corp, Laboratory Corp of America Holdings, 23andMe Holding Co, Quest Diagnostics Inc, Illumina Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Inc, and Centogene AG are among the leading companies operating in the Europe genetic testing services market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Genetic Testing Services Market - Key Industry Dynamics

• 4.1 Key Market Drivers
  • 4.1.1 Rising Prevalence of Genetic Diseases
  • 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines
  • 4.1.3 Growing Preference for Direct-To-Consumer (DTC) Genetic Testing
• 4.2 Market Restraints
  • 4.2.1 Social and Ethical Implications of Genetic Testing
  • 4.2.2 Affordability of Genetic Services
• 4.3 Market Opportunities
  • 4.3.1 Rising Demand for Pharmacogenomics
• 4.4 Future Trends
  • 4.4.1 Artificial Intelligence-Powered Genetic Testing
• 4.5 Impact Analysis:

5. Genetic Testing Services Market - Europe Market Analysis

• 5.1 Europe Genetic Testing Services Market Revenue (US$ Mn), 2022 - 2030

6. Europe Genetic Testing Services Market - Revenue and Forecast to 2030 - by Service Type

• 6.1 Overview
• 6.2 Europe Genetic Testing Services Market Revenue Share, by Service Type, 2022 & 2030 (%)
• 6.3 Predictive Testing
  • 6.3.1 Overview
  • 6.3.2 Predictive Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Carrier Testing
  • 6.4.1 Overview
  • 6.4.2 Carrier Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.5 Prenatal Testing
  • 6.5.1 Overview
  • 6.5.2 Prenatal Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.6 Newborn Screening
  • 6.6.1 Overview
  • 6.6.2 Newborn Screening: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.7 Others
  • 6.7.1 Overview
  • 6.7.2 Others: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Genetic Testing Services Market - Revenue and Forecast to 2030 - by Disease

• 7.1 Overview
• 7.2 Europe Genetic Testing Services Market Revenue Share, by Disease, 2022 & 2030 (%)
• 7.3 Cancer
  • 7.3.1 Overview
  • 7.3.2 Cancer: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Cardiovascular Diseases
  • 7.4.1 Overview
  • 7.4.2 Cardiovascular Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Metabolic Diseases
  • 7.5.1 Overview
  • 7.5.2 Metabolic Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Other Diseases
  • 7.6.1 Overview
  • 7.6.2 Other Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Genetic Testing Services Market - Revenue and Forecast to 2030 - by Service Provider

• 8.1 Overview
• 8.2 Europe Genetic Testing Services Market Revenue Share, by Service Provider, 2022 & 2030 (%)
• 8.3 Hospital-Based Laboratories
  • 8.3.1 Overview
  • 8.3.2 Hospital-Based Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Diagnostic Laboratories
  • 8.4.1 Overview
  • 8.4.2 Diagnostic Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Others
  • 8.5.1 Overview
  • 8.5.2 Others: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Genetic Testing Services Market - Country Analysis

• 9.1 Europe
  • 9.1.1 Europe Genetic Testing Services Market, by Country
    • 9.1.1.1 UK
      • 9.1.1.1.1 Overview
      • 9.1.1.1.2 UK Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.1.3 UK Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.1.4 UK Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.1.5 UK Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.2 Germany
      • 9.1.1.2.1 Overview
      • 9.1.1.2.2 Germany: Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.2.3 Germany: Europe Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.2.4 Germany: Europe Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.2.5 Germany: Europe Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.3 France
      • 9.1.1.3.1 Overview
      • 9.1.1.3.2 France Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.3.3 France Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.3.4 France Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.3.5 France Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.4 Italy
      • 9.1.1.4.1 Overview
      • 9.1.1.4.2 Italy Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.4.3 Italy Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.4.4 Italy Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.4.5 Italy Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.5 Spain
      • 9.1.1.5.1 Overview
      • 9.1.1.5.2 Spain Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.5.3 Spain Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.5.4 Spain Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.5.5 Spain Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.6 Rest of Europe
      • 9.1.1.6.1 Overview
      • 9.1.1.6.2 Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.6.3 Rest of Europe Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.6.4 Rest of Europe Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.6.5 Rest of Europe Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)

10. Genetic Testing Services Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in Genetic Testing Services Market
• 10.3 Organic Growth Strategies
  • 10.3.1 Overview
• 10.4 Inorganic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Eurofins Scientific SE
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Exact Sciences Corp
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Laboratory Corp of America Holdings
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 23andMe Holding Co
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Quest Diagnostics Inc
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Illumina Inc
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 F. Hoffmann-La Roche Ltd
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 NeoGenomics Inc
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments
• 11.9 Centogene AG
  • 11.9.1 Key Facts
  • 11.9.2 Business Description
  • 11.9.3 Products and Services
  • 11.9.4 Financial Overview
  • 11.9.5 SWOT Analysis
  • 11.9.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms